A 301

Nogotrienone is an anabolic steroid with fertility and contraceptive activity that has been studied as a therapeutic agent for hereditary angioneurotic edema.

Olamkicept (FE-301) is a soluble gp130-Fc-fusion protein that selectively inhibits interleukin 6 (IL-6) trans-signaling by binding to the soluble IL-6 receptor IL-6 complex.

Avosentan(Ro 67-0565; SPP-301) is a potent endothelin receptor (ETA) antagonist with strong inhibitory effects on endothelin-1-induced contraction and may have protective effects against chronic kidney disease. [2]

IMB-301 is a small molecular inhibitor via virtual screening according to the hA3G model.

TIK-301 is a chlorinated melatonin derivative and a potent, high-affinity, and orally active melatonin MT1 and MT2 receptors agonist (Kis: 0.081 nM and 0.042 nM, respectively). TIK-301 is also a 5-HT2B 5-HT2C receptor antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment.

PKUMDL-LTQ-301 is a potent inhibitor of HipA toxin. PKUMDL-LTQ-301 also inhibits E. coli persistence.

TT-301 is a cytokine inhibitor and glial cell inhibitor.

TRK-380 (TAC-301) is an effective and selective β3-adrenergic receptor agonist. TRK-380 improves formalin-induced frequent urination in rats and carbachol-induced bladder contraction in dogs (a decrease of 37.6%).

(Rac)-Tanomastat ((Rac)-BAY 12-9566) is a racemate of Tanomastat. Tanomastat (BAY 12-9566) is an orally active zinc carboxy-containing inhibitor of non-peptide biphenyl matrix metalloproteinases (MMPs) and inhibits MMP-2 (Ki: 11 nM), MMP-3 (Ki: 143 nM), MMP-9 (Ki: 301 nM), and MMP-13 (Ki: 1470 nM). In several experimental tumor models, Tanomastat exhibits anti-invasive and anti-metastatic effects.

LEI-301 is a novel potent inhibitor for the PLAAT family members, reducing the NAE levels, including anandamide, in cells overexpressing PLAAT2 or PLAAT5.

UH 301 is a 5-HT1A receptor antagonist.

LabMol-301, a chemical compound, effectively inhibits NS5 RdRp and NS2B-NS3pro activity with IC50 values of 0.8 μM and 7.4 μM, respectively. Additionally, it exhibits cytoprotective effects, safeguarding against Zika virus (ZIKV)-induced cell death.

LWG-301, an allosteric inhibitor of Glutaminase 1 (GLS1), demonstrates a potent inhibition with an IC50 value of 7 nM. It effectively impedes glutamine metabolism and elevates intracellular ROS levels, thereby inducing apoptosis. Additionally, LWG-301 shows moderate antitumor efficacy in the HCT116 xenograft model.

RU-301 is a novel pan-tam inhibitor

Zelminemab (AMG-301) is a humanized monoclonal antibody targeting the pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1) for use in neurological disorders.

Tosatoxumab (AR-301; KBSA301), a human immunoglobulin G1 monoclonal antibody, specifically targets and neutralizes S. aureus alpha-toxin (alpha-hemolysin; Hla) by binding to its N-terminal epitope. This interaction blocks the toxin's ability to form functional pore oligomers, crucial for its pathogenic activity. As a result, Tosatoxumab offers promising potential as an adjunctive passive immunotherapy alongside conventional antibiotics for S. aureus pneumonia [1] [2].

Cosibelimab (CK-301; TG-1501) is a fully human, high-affinity monoclonal antibody that inhibits PD-L1 by preventing its interaction with PD-1. Featuring a functional Fc domain, this compound effectively induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), targeting and eliminating PD-L1+ cell lines, including lymphoma cells [1].

Theraphotoxin-Tap1a (Tap1a) is a spider venom-derived peptide that acts as an inhibitor of sodium channels, displaying IC50 values of 80 nM for Na v 1.7 and 301 nM for Na v 1.1. It demonstrates analgesic effects [1].

Pancreastatin (37-52), human, is a biologically active fragment of CgA-derived peptide (residues 250–301) that inhibits insulin release from islet beta cells [1][2].

Nagrestipen, a variant of the human macrophage inflammatory protein-1 alpha (MIP-1α), also referred to as ECI 301, exhibits antitumor activity. It is employed in therapeutic trials focused on cancer, assessing its efficacy in the contexts of tumors, metastasis, radiation oncology, and the analysis of tumor metastasis [1].

4A7C-301, a Nurr1 agonist, exhibits potent neuroprotective effects in vitro and markedly mitigates neuropathological abnormalities while enhancing motor and olfactory functions in male mouse models with AAV2-mediated α-synuclein overexpression. This compound is applicable in Parkinson's disease research [1].

The compound 4A7C-301-Nurr1 agonist is a specific agonist for the nuclear receptor-related 1 (Nurr1). By binding to the Nurr1 ligand-binding domain with an IC50 value of 48.22 nM, it enhances the transcriptional activity of both Nurr1-LBD and the full-length Nurr1, as demonstrated in reporter assays using SK-N-BE(2)C human neuroblastoma cells, with EC50 values of 6.53 and 50-70 µM, respectively. Additionally, administration of 4A7C-301-Nurr1 agonist at a dosage of 5 mg/kg per day has been shown to mitigate dopaminergic cell death in the striatum and substantia nigra pars compacta and ameliorate motor and olfactory deficits in mouse models of Parkinson's disease, circumventing the induction of dyskinesia-like behaviors. These models were induced either by the neurotoxin MPTP or by overexpression of α-synuclein.

KIO-301, a photoswitchable HCN channel blocker, can be used as a vitreous light switch molecule to reactivate retinitis pigmentosa [1].

JKC 301, a selective Endothelin A receptor antagonist, attenuates the pressor effects of nicotine in rats and can be used to study cardiovascular disease caused by smoking [1] [2].